T4090 vs Rhopressa for Glaucoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests two doses of a new eye drop, T4090, against an existing treatment, Rhopressa®, to determine which is more effective and safer for lowering eye pressure. It targets individuals with open-angle glaucoma or ocular hypertension, conditions that cause high eye pressure. Candidates should have these conditions in both eyes and no recent eye injuries or infections. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, providing an opportunity to contribute to important advancements in eye care.
Do I have to stop taking my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research shows that T4090, a new eye drop under study, is being tested in two strengths (0.2% and 0.3%) for treating glaucoma. Since this study is in its early stages, limited information exists about how well people tolerate T4090. However, early studies usually focus on safety, suggesting that initial tests have likely shown some safety.
Rhopressa® is already approved for treating glaucoma, indicating it has undergone thorough testing and is considered safe for patients with this condition.
For those considering joining the trial, it is important to know that researchers are carefully monitoring both treatments for safety and side effects. Always discuss any risks and benefits with a doctor.12345Why are researchers excited about this trial's treatments?
Researchers are excited about T4090 for glaucoma because it offers a new approach to managing intraocular pressure, which is crucial for glaucoma patients. Unlike the standard treatments that often focus on aqueous humor outflow, T4090 is being tested in two concentrations (0.2% and 0.3%) and has the potential to provide more effective pressure reduction. This treatment could be a game-changer by offering an alternative for patients who might not respond well to existing options like prostaglandin analogs or beta-blockers. If successful, T4090 might offer better control with fewer side effects, enhancing patient outcomes and quality of life.
What evidence suggests that this trial's treatments could be effective for glaucoma?
Studies have shown that Rhopressa® effectively lowers eye pressure, crucial for managing glaucoma. One study found that Rhopressa® reduced eye pressure in 58% of cases that would have otherwise required more invasive treatments like laser therapy or surgery. In this trial, participants will receive either Rhopressa® or T4090. Early results suggest that T4090 might also help lower eye pressure. Researchers are comparing two strengths of T4090, 0.2% and 0.3%, to evaluate their effectiveness. While T4090 is still under investigation, there is hope it could become a new option for people with glaucoma.12678
Are You a Good Fit for This Trial?
This trial is for adults over 18 with Open-Angle Glaucoma or Ocular Hypertension in both eyes. Participants must understand the study and sign a consent form.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive T4090 or Rhopressa® ophthalmic solution to assess ocular hypotensive efficacy and safety
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Rhopressa®
- T4090
Find a Clinic Near You
Who Is Running the Clinical Trial?
Laboratoires Thea
Lead Sponsor